Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BGC Partners Q4 Profit Decreases - Quick Facts

RELATED NEWS
Trade BGCP now with 

BGC Partners, Inc. (BGCP: Quote) posted fourth-quarter net income for fully diluted shares of $7.6 million or $0.03 per share versus $31.5 million or $0.12 per share last year.

Total revenues for the three-month period improved year-over-year to $355.17 million from $321.76 million.

Analysts polled by Thomson Reuters expected the company to record revenues of $352.08 million for the quarter. Analysts' estimates typically exclude special items.

Further, the company's board of directors declared a quarterly cash dividend of $0.17 per share payable on March 28, 2012 to Class A and Class B common stockholders of record as of March 14, 2012. The ex-dividend date will be March 12, 2012.

Click here to receive FREE breaking news email alerts for BGC Partners Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Before heading to New York for meetings with other world leaders at the United Nations, President Barack Obama delivered a statement on Tuesday regarding U.S. airstrikes in Syria. Obama highlighted the fact that the U.S. was joined in the attack by Saudi Arabia, the United Arab Emirates, Jordan, Bahrain, and Qatar. After recovering from an initial move to the downside, stocks have shown a lack of direction over the course of the trading day on Tuesday. The choppy trading comes on the heels of the notable pullback seen in the previous session. With lawmakers failing to address corporate tax reform before adjourning for the campaign season, the Treasury Department announced Monday that it is taking targeted action to reduce the tax benefits of corporate tax inversions.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.